

# Curriculum Vitae

3.2.2020

**Professor Dr. med Carsten Grüllich**

**Medical Oncologist and Hematologist**

Current Job Title

**Head of section for conservative and translational  
Uro-Oncology**

**Head of the clinical trial unit for GU**

**Consultant or Oncology/Hematology**

## OFFICE ADDRESS

Institution

University Hospital Dresden

Department

Dept. of Urology

Street

Fetscherstr. 74

Place

01307 Dresden

Date of Birth

15.08.1965

Nationality

German

## CURRENT RESPONSIBILITIES

**Head of Uro-Oncology at Universitätsklinikum  
Carl Gustav Carus Dresden**

Clinical consultant for outpatient and inpatient care

Head of clinical trial unit

## EDUCATION

1972 - 1976

Hochtorgrundschule Neustadt i.H.

1976 - 1985

Freie Waldorfschule Lübeck

1985 - 1986

Zivildienst

4/1987 – 10/1993

Freiburg University Medical School

## DEGREES EARNED

10/1993	Medical Approbation (temporary for Arzt IP)
10/1995	Full medical Approbation
3/1996	Medical Doctorate
10/2002	Internal Medicine Board
3/2004	Hematology/Oncology Board
1/2010	Habilitation, Venia legendi for internal medicine “ Apoptosemechanismen in der gesunden und malignen Hämatopoese“
5/2018	Prof. (apl) for medicine at Heidelberg University

## EMPLOYMENT HISTORY

3/1994 – 10/1996	Resident <b>University Freiburg Medical Center</b> , Dpt. Hematology/Oncology, Freiburg, Germany
10/1996 – 9/1999	Postdoctoral Fellow <b>Memorial Sloan Kettering Cancer Center</b> , New York, USA
9/1999 – 8/2008	Resident and attending physician at <b>University Freiburg Medical Center</b> , Dpt. Hematology/ Oncology, Freiburg, Germany
08/2008-3/19	Consulting physician <b>NCT-Heidelberg</b> , Dept. of Medical Oncology (Director: Prof. Dirk Jäger)
1/2011-3/19	Head of clinical trial unit GU and GI tumors
5/2016-3/19	Head of the clinical section for translational Uro-Oncology

## Funding

1997-1999	Krebshilfe Fellowship	120.000€
2000-2005	Intramural funding University Freiburg fellowship):	100.000€
From 2008	Industry funding	appr. 2.000 000€

## SELECTED PUBLICATIONS (Medline)

- (1) Bose R, Chen P, Loconti A, **Grüllich C**, Abrams JM, Kolesnick RN. Ceramide generation by the Reaper protein is not blocked by the caspase inhibitor, p35. *J Biol Chem* 1998;273:28852-9.
- (2) **Grüllich C**, Sullards MC, Fuks Z, Merrill AH, Jr., Kolesnick R. CD95(Fas/APO-1) signals ceramide generation independent of the effector stage of apoptosis. *J Biol Chem* 2000;275:8650-6.
- (3) **Grüllich C**, Duvoisin RM, Wiedmann M, Van LK. Inhibition of 15-lipoxygenase leads to delayed organelle degradation in the reticulocyte. *FEBS Lett* 2001;489:51-4.
- (4) **Grüllich C**, Baumert TF, Blum HE. Acute *Mycoplasma pneumoniae* infection presenting as cholestatic hepatitis. *J Clin Microbiol* 2003;41:514-5.
- (5) **Grüllich C**, Richter M, Exner S, Finke J. Fas ligand is not constitutively expressed in low-grade B-cell lymphoma and B-lymphoblastoid cells. *Eur J Haematol* 2003;71:184-8.
- (6) Muller CI, Zeiser R, **Grüllich C**, Finke J, Bertz H, Schmitt-Graff A, et al. Intestinal cryptosporidiosis mimicking acute graft-versus-host disease following matched unrelated hematopoietic stem cell transplantation. *Transplantation* 2004;77:1478-9.
- (7) Zeiser R, **Grüllich C**, Bertz H, Pantazis G, Hufert FT, Bley TA, et al. Late cytomegalovirus polyradiculopathy following haploidentical CD34+-selected hematopoietic stem cell transplantation. *Bone Marrow Transplant* 2004;33:243-5.
- (8) Baumert TF, Yang C, Schurmann P, Kock J, Ziegler C, **Grüllich C**, et al. Hepatitis B virus mutations associated with fulminant hepatitis induce apoptosis in primary Tupaia hepatocytes. *Hepatology* 2005;41:247-56.
- (9) Zeiser R, Spyridonidis A, Wasch R, Ihorst G, **Grüllich C**, Bertz H, et al. Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. *Leukemia* 2005;19:814-21.
- (10) **Grüllich C**, McGoldrick S, Zeiser R, Finke J. The death receptor pathway is not involved in alloreactive T-cell induced mitochondrial membrane permeability. *Leuk Lymphoma* 2005;46:1207-16.
- (11) Spyridonidis A, Bertz H, Ihorst G, **Grüllich C**, Finke J. Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (> or = 60 years) with active myeloid malignancies. *Blood* 2005;105:4147-8.

- (12) Heining C, Spyridonidis A, Bernhardt E, Schulte-Monting J, Behringer D, **Grüllich C**, et al. Lymphocyte reconstitution following allogeneic hematopoietic stem cell transplantation: a retrospective study including 148 patients. *Bone Marrow Transplant* 2007;39:613-22.
- (13) **Grüllich C**, Bertz H, Spyridonidis A, Muller CI, Finke J. A fludarabine, thiotepea reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation. *Bone Marrow Transplant* 2008;41:845-50.
- (14) **Grüllich C**, Fricke V, Finke J. Ex vivo detection of primary leukemia cells resistant to granule cytotoxin-induced cell death: a rapid isolation method to study granzyme-B-mediated cell death. *Ann Hematol* 2008;87:701-8.
- (15) Ruckert A, Glimm H, Lubbert M, **Grüllich C**. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. *Lupus* 2008;17:757-60.
- (16) **Grüllich C**, Ziegler C, Finke J. Rabbit anti T-lymphocyte globulin induces apoptosis in peripheral blood mononuclear cell compartments and leukemia cells, while hematopoietic stem cells are apoptosis resistant. *Biol Blood Marrow Transplant* 2009;15:173-82.
- (17) Bertz H, Spyridonidis A, Wasch R, **Grüllich C**, Egger M, Finke J. A novel GVHD-prophylaxis with low-dose alemtuzumab in allogeneic sibling or unrelated donor hematopoietic cell transplantation: the feasibility of deescalation. *Biol Blood Marrow Transplant* 2009;15:1563-70.
- (18) Schroettner P, **Gruellich C**, Hasskarl J, Waller CF. Achievement of a continuous complete remission in a kidney transplant patient with advanced donor-derived small cell carcinoma. *Transplantation* 2010;90:94-5.
- (19) **Grüllich C**, von Kalle C: Recent developments and future perspectives of personalized oncology. *Onkologie* 2012, 35 Suppl 1:4-7.
- (20) Zeiser R, Spyridonidis A, Wasch R, Ihorst G, **Grüllich C**, Bertz H, Finke J: Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. *Leukemia* 2005, **19**:814-821.
- (21) Hartmut Bertz, Alexandros Spyridonidis, Gabriele Ihorst, Monika Engelhardt, **Carsten Grüllich**, Ralph Wäsch, Reinhard Marks, Jürgen Finke. Marrow versus Blood-Derived Stem Cell Grafts for Allogeneic Transplantation from Unrelated Donors in Patients with Active Myeloid Leukemia or Myelodysplasia. *Biol Blood Marrow Transplant* Volume 18, Issue 6, June 2012, Pages 894–902
- (22) Sedlacek O, **Grüllich C**, Röthke M, Schlemmer HP, Kauczor HU. Organ toxicity of medicinal tumor therapy: morphological correlates. *Radiologe*. 2013 Apr;53(4):329-35. doi: 10.1007/s00117-012-2428-7
- (23) Foerster R. · Welzel T. · Debus J. · **Gruellich C**. · Jaeger D. · Potthoff K. Posterior Reversible Leukoencephalopathy Syndrome Associated with Pazopanib. *Case Rep Oncol* 2013;6:204-208 (DOI:10.1159/000350742)

- (24) Hadaschik B, Pahernik S, **Grüllich C**, Sültmann H, Jäger D, von Kalle C, Duensing S, Hohenfellner M. Urology in the concept of comprehensive cancer centers. *Urologe A*. 2013 Sep;52(9):1283-9. doi: 10.1007/s00120-013-3313-3
- (25) Fritsch K, Finke J, **Grüllich C**. Suppression of granzyme B activity and caspase-3 activation in leukaemia cells constitutively expressing the protease inhibitor 9. *Ann Hematol*. 2013 Dec;92(12):1603-9. doi: 10.1007/s00277-013-1846-6. Epub 2013 Jul 28.
- (26) **Carsten Grüllich**. Cabozantinib: A MET, RET, and VEGFR2 Tyrosine Kinase Inhibitor Small Molecules in Oncology, *Recent Results in Cancer Research* Volume 201, 2014, pp 207-21
- (27) Christian Ziegler, Jürgen Finke, **Carsten Grüllich**. Rabbit anti-T-lymphocyte globulin (ATG) persists with differential reactivity in patients' sera after full hematopoetic regeneration from allogeneic stem cell transplantation. *Transplant Immunology*. Volume 30, Issue 4, May 2014, Pages 136–139
- (28) Falk Roeder, Burkhard Lehner, Thomas Schmitt, Bernd Kasper, Gerlinde Egerer, Oliver Sedlacek, **Carsten Grüllich**, Gunhild Mechtersheimer, Patrick Wuchter, Frank W Hensley, Peter E Huber, Juergen Debus and Marc BischofExcellent local control with IOERT and postoperative EBRT in high grade extremity sarcoma: results from a subgroup analysis of a prospective trial. *BMC Cancer* 2014, 14:350 doi:10.1186/1471-2407-14-350
- (29) Meike Schneider, Julia Schüler, Rouven Höfflin, Nina Korzeniewski, **Carsten Grüllich**, Wilfried Roth, Dogu Teber, Boris Hadaschik, Sascha Pahernik, Markus Hohenfellner, Stefan Duensing. Phenotypic drug screening and target validation for improved personalized therapy reveal the complexity of phenotype-genotype correlations in clear cell renal cell carcinoma. *Urologic Oncology: Seminars and Original Investigations*. DOI: 10.1016/j.urolonc.2014.03.011
- (30) Meike Schneider, Nina Korzeniewski, Konstanze Merkle, Julia Schüler, **Carsten Grüllich**, Boris Hadaschik, Markus Hohenfellner, Stefan Duensing. The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal—Implications for targeted therapies. DOI: 10.1016/j.urolonc.2014.06.001
- (31) Thomas Höfner<sup>1</sup>, Sonia Vallet<sup>2</sup>, Boris A Hadaschik<sup>1</sup>, Sascha Pahernik<sup>1</sup>, Stefan Duensing<sup>1,3</sup> Markus Hohenfellner<sup>1</sup>, Dirk Jäger<sup>2</sup>, **Carsten Grüllich**<sup>2</sup> Docetaxel followed by abiraterone in metastatic castration resistant prostate cancer. Efficacy and predictive parameters in a large single center cohort. *World Journal of Urology* 2014 June 2015, Volume 33, Issue 6, pp 833–839
- (32) Björn Georgi, Nina Korzeniewski, Boris Hadaschik, **Carsten Grüllich**, Wilfried Roth, Holger Sültmann, Sascha Pahernik, Markus Hohenfellner, Stefan Duensing. Evolving therapeutic concepts in prostate cancer based on genome-wide analyses *International Journal of Oncology*. Published online on: Monday, July 28, 2014 DOI: 10.3892/ijo.2014.2567
- (33) Johannes Huber, Andreas Ihrig, Eva Winkler, Anette Brechtel, Hans-Christoph Friederich, Wolfgang Herzog, Martin Frank, **Carsten Grüllich**, Peter Hallscheidt, Martin Zeier, Sascha Pahernik, Markus Hohenfellner. Interdisciplinary counseling service for renal malignancies: A patient-centered approach to raise guideline adherence *Urol. Oncology*, Published Online: November 29, 2014 DOI: <http://dx.doi.org/10.1016/j.urolonc.2014.10.017>

- (34) Zhou X, Tolstov Y, Arslan A, **Grüllich C**, Pahernik S, Hohenfellner M, Duensing S. Harnessing the p53-PUMA axis to overcome DNA damage resistance in renal cell carcinoma. *Neoplasia* 2014 doi:10.1016/j.neo.2014.09.012
- (35) Sonia Vallet, Sascha Pahernik, Thomas Höfner, Georgi Tosev, Boris Hadaschik, Stefan Duensing, Oliver Sedlacek, Markus Hohenfellner, Dirk Jäger, **Carsten Grüllich**. Efficacy of Targeted Treatment Beyond Third-Line Therapy in Metastatic Kidney Cancer: Retrospective Analysis From a Large-Volume Cancer Center. *Clinical Genitourinary Cancer* 2014 doi:10.1016/j.clgc.2014.12.012
- (36) R. Höfflin, W. Roth, H. Sültmann, **C. Grüllich**, G. Hatiboglu, J. Nyarangi-Dix, G. Schönberg, D. Teber, B. Hadaschik, S. Pahernik, M. Hohenfellner, Prof. Dr. S. Duensing Intratumorale Heterogenität des Nierenzellkarzinoms. *Der Urologe*, March 2015; 12 Mar 2015
- (37) Christian Ziegler, Jürgen Finke , **Carsten Grüllich**. Features of cell death, mitochondrial activation and caspase dependence of rabbit anti-T-lymphocyte globulin signaling in lymphoblastic Jurkat cells are distinct from classical apoptosis signaling of CD95. *Leukemia and Lymphoma* online 25, May 2015.
- (38) David Carl, **Carsten Grüllich**, Steffen Hering and Martin Schabet. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. *BMC Research Notes* 2015, 8:316
- (39) Toni K. Choueiri, M.D., Bernard Escudier, M.D., Thomas Powles, M.D., Paul N. Mainwaring, M.D., Brian I. Rini, M.D., Frede Donskov, M.D., Ph.D., Hans Hammers, M.D., Ph.D., Thomas E. Hutson, D.O., Pharm.D., Jae-Lyun Lee, M.D., Ph.D., Katriina Peltola, M.D., Ph.D., Bruce J. Roth, M.D., Georg A. Bjarnason, M.D., Lajos Géczi, M.D., Ph.D., Bhumsuk Keam, M.D., Ph.D., Pablo Maroto, M.D., Daniel Y.C. Heng, M.D., M.P.H, Manuela Schmidinger, M.D., Philip W. Kantoff, M.D., Anne Borgman-Hagey, M.D., Colin Hessel, M.S., Christian Scheffold, M.D., Ph.D., Gisela M. Schwab, M.D., Nizar M. Tannir, M.D., and Robert J. Motzer, M.D. for the METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2015; 373:1814-1823 November 5, 2015 DOI: 10.1056/NEJMoa1510016. Member of the study group.
- (40) M Kordes, M Röring, C Heining, S Braun, B Hutter, D Richter, C Geörg, C Scholl, S Gröschel, W Roth, A Rosenwald, E Geissinger, C von Kalle, D Jäger, B Brors, W Weichert, C Grüllich, H Glimm, T Brummer and S Fröhling. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling. *Leukemia* doi:10.1038/leu.2015.319; accepted article preview online November 19, 2015
- (41) Xiaoguang Zhou, Jieli Li,, Christina Marx, Yanis Tolstov, Geraldine Rauch, Esther Herpel‡, §, Stephan Macher-Goepfinger‡, Wilfried Roth‡, **Carsten Grüllich**, Sascha Pahernik, Markus Hohenfellner, Stefan Duensing. Uncoupling of PUMA Expression and Apoptosis Contributes to Functional Heterogeneity in Renal Cell Carcinoma — Prognostic and Translational Implications. *Translational Oncology* Volume 8, Issue 6, December 2015, Pages 480–486
- (42) Josef Mang, Nina Korzeniewski, Dimo Dietrich, Verena Sailer, Yanis Tolstov, Sam Searcy, Jost von Hardenberg, Sven Perner, Glen Kristiansen, Alexander Marx, Wilfried Roth, Esther Herpel, **Carsten Grüllich**, Valentin Popeneciu, Sascha Pahernik, Boris Hadaschik, Markus Hohenfellner, Stefan Duensing. Prognostic Significance and Functional Role of CEP57 in Prostate Cancer. *Translational Oncology*, Volume 8, Issue 6, December 2015, Pages 487–496

- (43) **Carsten Grüllich**, Sonia Vallet, Christopher Hecht, Stefan Duensing, Boris Hadaschik, Dirk Jäger, Markus Hohenfellner and Sascha Pahernik. Local salvage therapy for late ( $\geq 2$  years) metastatic and local relapse of renal cell cancer is a potentially curative treatment irrespective of the site of recurrence. *Urologic Oncology* doi:10.1016/j.urolonc.2015.11.022.
- (44) YueJun Du, **Carsten Grüllich**, Boris Hadaschik, Gencay Hatiboglu, Markus Hohenfellner, Sascha Pahernik. Local Recurrence After Curative Surgical Treatment of Renal Cell Cancer: A Study of 91 Patients. *Clinical Genitourinary Cancer* 2016 doi:10.1016/j.clgc.2016.01.012
- (45) S. Zschäbitz, F. Lasitschka, D. Jäger, **C. Grüllich**. Activity of immune checkpoint inhibition in platinum refractory germ cell tumors. *Annals of Oncology* (2016) 27 (7): 1356-1360.
- (46) Rouven Höfflin, Bernd Lahrmann, Gregor Warsow, Daniel Hübschmann, Cathleen Spath, Britta Walter, Xin Chen, Luisa Hofer, Stephan Macher-Goeppinger, Yanis Tolstov, Nina Korzeniewski, Anette Duensing, **Carsten Grüllich**, Dirk Jäger, Sven Perner, Gita Schönberg, Sanjay Isaac, Joanne Nyarangi-Dix, Gencay Hatiboglu, Dogu Teber, Boris Hadaschik, Sascha Pahernik, Wilfried Roth, Roland Eils, Matthias Schlessner, Holger Sülthmann, Markus Hohenfellner, Niels Grabe, and Stefan Duensing. Spatial niche formation but not malignant progression is a driving force for intratumoral heterogeneity. *Nature Communications*, 13.06.16 DOI: 10.1038/ncomms11845
- (47) YueJun Du <sup>1,4</sup>, Sascha Pahernik<sup>1</sup>, Boris Hadaschik<sup>1</sup>, Dogu Teber<sup>1</sup>, Stefan Duensing<sup>2</sup>, Dirk Jäger<sup>3</sup> Markus Hohenfellner<sup>1</sup>, **Carsten Grüllich**<sup>3</sup>. Survival and prognostic factors of renal cell cancer patients with bone metastasis in the era of targeted therapy: a single institution analysis. *Urologic Oncology* Volume 34, Issue 10, October 2016, Pages 433.e1–433.e8.
- (48) YueJun Du, Sascha Pahernik, Boris Hadaschik, Dogu Teber, Stefan Duensing, Dirk Jäger, Markus Hohenfellner, **Carsten Grüllich** Impact of resection and systemic therapy on the survival of patients with brain metastasis of metastatic renal cell carcinoma. *Journal of Neuro-Oncology* .October 2016, Volume 130, Issue 1, pp 221–228
- (49) C. Nientiedt, Y. Tolstov, A.-L. Volckmar, V. Endris, D. Bonekamp, U. Haberkorn, D. Jäger, H. Sülthmann, A. Stenzinger, M. Hohenfellner, **C. Grüllich**, S. Duensing. PARP inhibition in BRCA2-mutated prostate cancer . *Annals of Oncology Ann Oncol* (2017) 28 (1): 189-191.
- (50) C.Grüllich. Übersicht – Neue Immuntherapien in der Uro-Onkologie. *TumorDiagn u Ther* 2016; 37(03): 134-136
- (51) Stephan Macher-Goeppinger, Martina Keith, Volker Endris, Roland Penzel, Katrin E. Tagscherer, Sascha Pahernik, Markus Hohenfellner, Humphrey Gardner, Carsten Grüllich, Peter Schirmacher, Wilfried Roth. MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker, *Oncotarget* November 24, 2016
- (52) Gencay Hatiboglu, Markus Hohenfellner, Aysenur Arslan, Boris Hadaschik, Dogu Teber, Jan Philipp Radtke, Peter Hallscheidt, Yanis Tolstov, Wilfried Roth, Carsten Grüllich, Johannes Huesing, Stefan Duensing, Sascha Pahernik. Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma, *Langenbeck's Archives of Surgery*. First Online: 23 December 2016
- (53) Weibin Hou, Rouven Hoefflin, Carsten Grüllich. Stefan Duensing. Molecular Heterogeneity of Renal Cell Carcinoma. January 2017. In book: *Urologic Oncology*, pp.1-8

- (54) Stefanie Zschäbitz, Sonia Vallet, Boris Hadaschik, Daniel Debatin, Stefan Fuxius, Andreas Karcher, Sascha Pahernik, Cathleen Spath, Stefan Duensing, Dirk Jäger, Markus Hohenfellner, **Carsten Grüllich**. Efficacy of Cabazitaxel Treatment in Metastatic Castration Resistant Prostate Cancer in Second and Later Lines. An Experience from Two German Centers. *Journal of cancer* 2017; 8(4): 507-512. doi: 10.7150/jca.17644
- (55) Stefanie Zschäbitz, Felix Lasitschka, Boris Hadaschik, Ralf-Dieter Hofheinz, , Kathleen Jentsch-Ullrich, Marcus Grüner, Dirk Jäger, **Carsten Grüllich**. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. *European Journal of Cancer*. Volume 76, May 2017, Pages 1–7
- (56) L. Hofer, C. Gasch, G. Hatiboglu, J. Motsch, **C. Grüllich**, S. Duensing, M. Hohenfellner. Level-IV-Cavathrombus. Eine seltene Diagnose bei Patienten mit Nierenzellkarzinom Der Urologe. pp 1–6. 27 March 2017
- (57) Jan Pfeiffenberger, Tatjana Zimmermann, Daniel N. Gotthardt, Christoph Springfield<sup>2,8</sup>, Wolfgang Stremmel, Peter Schirmacher, Henning Schulze-Bergkamen, Arianeb Mehrabi<sup>5,8</sup>, Christoph W. Michalski, Katrin Hoffmann, Nikolas Kortes , Boris Radeleff ,Uwe Haberkorn, Clemens Kratochwil, Karl Heinz Weiss, **Carsten Grüllich**. Outcome results of treatment with selective internal radiation therapy (SIRT) in patients with hepatocellular carcinoma. A single center experience. *JCT Vol.8 No.4*, April 2017
- (58) YueJun Du, Sascha Pahernik, Matthias Kwol, Stefan Fuxius, Boris Hadaschik, Dogu Teber, Stefan Duensing, Annette Kaiser, Markus Hohenfellner, **Carsten Grüllich**. Collecting Duct (Bellini Duct) Renal Cell Carcinoma: Oncologic outcome and therapeutic management *Journal of Cancer Therapy* 2017, 8, 413-422
- (59) Steffen Dietz,\* Holger Sültmann\*, YueJun Du, Eva Reisinger, Anja Lisa Riediger, Anna-Lena Volckmar, Albrecht Stenzinger, Matthias Schlesner, Dirk Jäger, Markus Hohenfellner, Stefan Duensing, **Carsten Grüllich#** and Sascha Pahernik#, Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy. *Oncotarget* May 23, 2017 # **shared senior authors**
- (60) Peter J Goebell, Christian Doehn, **Carsten Grüllich**, Viktor Grünwald, Thomas Steiner, Rainer Ehneß, Manfred Welslau. The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape. *Future Oncology* May 19,2017
- (61) Cathleen Nientiedt, Martina Heller, Volker Endris, Anna-Lena Volckmar, Stefanie Zschäbitz, Maria Tapia-Lalena, Anette Duensing, Dirk Jaeger, Peter Schirmacher, Holger Sültmann, Albrecht Stenzinger, Markus Hohenfellner, **Carsten Grüllich#**, and Stefan Duensing#. Mutations in BRCA2 and taxane resistance in prostate cancer *Nature scientific reports* 2017; 7: 4574 # **shared senior authors**
- (62) Friederike Scharhag-Rosenberger, Joachim Wiskemann, Sonia Vallet, Martin Georg Haag, Emanuel Schembri, Dirk Jäger, **Carsten Grüllich**. Resistance training as supportive measure in advanced cancer patients undergoing TKI therapy a controlled feasibility trial. *Supportive Care in Cancer* 2017 Jun 30.
- (63) Andreas Ihrig, Imad Maatouk, Susanne Fink, Sascha Pahernik, Caner Süsal, Johannes Huber, Markus Hohenfellner, Martin Zeier and Carsten Grüllich . Results of a patient survey for



assessment services in renal transplant patients with a history of cancer. Progress in transplantation. September 28, 2017

- (64) **C.Grüllich**. Immunotherapy as modern tumor treatment. Radiologe. 2017 Sep 4.
- (65) Christian Menzer, **Carsten Gruellich**, Jessica C. Hassel. Editorial on the use of immunotherapy in renal-cell carcinoma—promising results in combination therapy with ipilimumab and nivolumab. Transl Cancer Res 2017;6 (Suppl 7):S1208-S1211.
- (66) Xin Chen, Christof Bernemann, Yuri Tolkach, Martina Heller, Cathleen Nientiedt, Michael Falkenstein, Esther Herpel, Maximilian Jenzer, **Carsten Grüllich**, Dirk Jäger, Holger Sültmann, Anette Duensing, Sven Perner, Marcus V. Cronauer, Carsten Stephan, Jürgen Debus, Andres Jan Schrader, Glen Kristiansen, Markus Hohenfellner, Stefan Duensing. Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy. Urologic Oncology: Seminars and Original Investigations. Available online 1 December 2017
- (67) Lukas Barwitz, Anne Berger, Stefanie Zschaebitz, Max Jenzer, Cathleen Nientiedt, Stefan Duensing, Dirk Jäger, Dogu Teber, Markus Hohenfellner, Carsten Grüllich. Efficacy of Different Second-Line Therapy Regimens in Metastatic Urothelial Carcinoma. The Open Urology & Nephrology Journal, 2017, 10
- (68) Svenja Dieffenbacher, Stefanie Zschäbitz, Luisa Hofer, Gencay Hatiboglu, Weibin Hou, Markus Hohenfellner, Stefan Duensing, Holger Sültmann, Sascha Pahernik, **Carsten Grüllich**. Prospective, single center trial of next generation sequencing analysis in metastatic renal cell cancer: The MORE-TRIAL. Future Science 14 March 2018
- (69) Ferdinand Toberer, Alexander Enk, Wolfgang Hartschuh, **Carsten Grüllich**. Testicular choriocarcinoma with cutaneous metastasis in a 19-year-old man. Journal of Cutaneous Pathology. 17 April 2018.
- (70) Stefanie Zschäbitz, Florian A Distler, Benjamin Krieger, Patrick Wuchter, Kerstin Schäfer-Eckart<sup>3</sup>, Maximilian Jenzer<sup>1</sup>, Markus Hohenfellner, Peter Dreger, Georg Martin Haag, Dirk Jäger, Sascha Pahernik and **Carsten Grüllich**. Survival outcomes of patients with germ cell tumors treated with high-dose chemotherapy for refractory or relapsing disease. Oncotarget Oncotarget, 2018, Vol. 9, (No. 32), pp: 22537-22545
- (71) Gregor Warsow, Daniel Hübschmann, Kortine Kleinheinz, Cathleen Nientiedt, Martina Heller, Laura Van Coile, Yanis Tolstov, Lukas Trennheuser, Kathrin Wiczorek, Carine Pecqueux, Claudia Gasch, Timur Kuru, Joanne Nyarangi-Dix, Gencay Hatiboglu, Dogu Teber, Sven Perner, Albrecht Stenzinger, Wilfried Roth, Boris Hadaschik, Sascha Pahernik, Dirk Jäger, **Carsten Grüllich**, Anette Duensing, Roland Eils, Matthias Schlesner, Holger Sültmann, Markus Hohenfellner & Stefan Duensing. Genomic features of renal cell carcinoma with venous tumor thrombus, Scientific Reports volume 8, 10 May 2018.
- (72) Carine Pecqueux, Aysenur Arslan, Martina Heller, Michael Falkenstein, Adam Kaczorowski, Yanis Tolstov, Holger Sültmann, **Carsten Grüllich**, Esther Herpel, Anette Duensing, Glen Kristiansen, Markus Hohenfellner, Nora M. Navone, Stefan Duensing. FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer. Urologic Oncology Volume 36, Issue 8, August 2018, Pages 365.e15-365.e26

- (73) Anne Katrin Berger, Stephan Lücke, Ulrich Abel, Georg Martin Haag, **Carsten Grüllich**, Annika Stange, Mareike Dietrich, Leonidas Apostolidis, Angelika Freitag, Claudia Trierweiler, Carl von Gall, Jennifer Ose, Frederik Giesel, Tim Frederik Weber, Florian Lordick, Uwe Haberkorn & Dirk Jäger. Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial. *British Journal of Cancer* volume 119, pages170–175 (2018)
- (74) **Carsten Grüllich** Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. *Small Molecules in Oncology* pp 67-75. 2 August 2018
- (75) Stefanie Zschäbitz **Carsten Grüllich**. Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFR $\alpha$ , KIT and RET. *Small Molecules in Oncology* pp 187-98. 2 August 2018
- (76) Claudia Kesch, Jan-Philipp Radtke, Axel Wintsche, Manuel Wiesenfarth, Mariska Luttje, Claudia Gasch, Svenja Dieffenbacher, Carine Pecqueux, Dogu Teber, Gencay Hatiboglu, Joanne Nyarangi-Dix, Tobias Simpfindörfer, Gita Schönberg, Antonia Dimitrakopoulou-Strauss, Martin Freitag, Anette Duensing, **Carsten Grüllich**, Dirk Jäger, Michael Götz, Niels Grabe, Michal-Ruth Schweiger, Sascha Pahernik, Sven Perner, Esther Herpel, Wilfried Roth, Kathrin Wiecezorek, Klaus Maier-Hein, Jürgen Debus, Uwe Haberkorn, Frederik Giesel, Jörg Galle, Boris Hadaschik, Heinz-Peter Schlemmer, Markus Hohenfellner, David Bonekamp, Holger Sültmann, Stefan Duensing. Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer. *Scientific Reports*, Volume 8, Article number: 16708 (2018)
- (77) Leonidas Apostolidis, Cathleen Nientiedt, Eva Caroline Winkler, Anne Katrin Berger, Clemens Kratochwil, Annette Kaiser, Anne-Sophie Becker, Dirk Jäger, Markus Hohenfellner, Clemens Hüttenbrink, Sascha Pahernik, Florian A. Distler and **Carsten Grüllich**. Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. *Oncotarget*, 2019, Vol. 10, (No. 1), pp: 17-29
- (78) Rexer, H; Hammerer, P ; **Grüllich, C**. First and Second-line Therapy for metastatic castration-refractory Prostate Cancer (mCRPC) A Phase II Study of Nivolumab in combination with Rucaparib, Docetaxel or Enzalutamide in Men with castration-resistant metastatic Prostate Cancer (CheckMate-9KD) - AP 103/18 of AUO. *UROLOGE*, Volume: 58, Issue: 4 Pages: 475-476
- (79) Christian Doehn, **Carsten Grüllich**, Heidrun Rexer: *Anti-PD-L1-Antikörper bei hohem Rezidivrisiko nach Nephrektomie*. 02/2019; 23(2):16-17., DOI:10.1007/s00092-019-2144-y
- (80) Emanuel Buck, Martin Sprick, Matthias M. Gaida, **Carsten Grüllich**, Tim Frederik Weber, Esther Herpel, Thomas Bruckner, Ronald Koschny: *Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer*. *Oncology letters* 02/2019; 17(4)., DOI:10.3892/ol.2019.10043
- (81) **Carsten Gruellich**, Renal Cell Carcinoma. *ONKOLOGE* Volume: 25 Issue: 6 Pages: 482-482 Published: JUN 2019
- (82) **Carsten Gruellich**; Klaus Hoeffken. Many New Aspects in Diagnostics and Treatment of Renal Cell Cancer. *ONKOLOGE* Volume: 25 Issue: 6 Pages: 480-481 Published: JUN 2019
- (83) Seitz, AK ; Heck, MM ; Kamer, M. W. ; **Grüllich, C**. Molecular tumor board prostate cancer. *UROLOGE*. Volume: 58. Issue: 7. Pages: 752-759. Published: JUL 2019

- (84) Maximilian Jenzer, Peter Keß, Cathleen Nientiedt, Volker Endris, Maximilian Kippenberger, Jonas Leichsenring, Fabian Stögbauer, Josh Haimes, Skyler Mishkin, Brian Kudlow, Adam Kaczorowski, Stefanie Zschäbitz, Anna-Lena Volckmar, Holger Sültmann, Dirk Jäger, Anette Duensing, Peter Schirmacher, Markus Hohenfellner, **Carsten Grüllich**#, Albrecht Stenzinger#, Stefan Duensing#. The BRCA2 mutation status shapes the immune phenotype of prostate cancer. *Cancer Immunology, Immunotherapy*. October 2019, Volume 68, Issue 10, pp 1621–1633 # shared senior authors
- (85) Andreas Mock, Stefanie Zschäbitz, Romy Kirsten, Matthias Scheffler, Barbara Wolf, Christel Herold-Mende, Rebecca Kramer, Elena Busch, Maximilian Jenzer, Dirk Jäger, **Carsten Grüllich**. Serum very long-chain fatty acid-containing lipids predict response to immune checkpoint inhibitors in urological cancers. *Cancer Immunology, Immunotherapy*. December 2019, Volume 68, Issue 12, pp 2005–2014
- (86) Elizabeth Alwers, Lina Jansen, Hendrik Bläker, Matthias Kloor, Katrin E. Tagscherer, Wilfried Roth, Daniel Boakye, Esther Herpel, **Carsten Grüllich**, Jenny Chang-Claude, Hermann Brenner, Michael Hoffmeister. Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study. *Molecular Oncology*, 09 December 2019 <https://doi.org/10.1002/1878-0261.12611>
- (87) Frede Donskov, Robert J. Motzer, Eric Voog, Elizabeth Hovey, **Carsten Grüllich**, Louise M. Nott, Katharine Cuff, Thierry Gil, Niels Viggo Jensen, Christine Chevreau, Sylvie Negrier, Reinhard Depenbusch, Lothar Bergmann, Izzy Cornelio, Anne Champsaur, Bernard Escudier, Sumanta Pal, Thomas Powles, Toni K. Choueiri. Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma *European Journal of Cancer*, Volume 126, February 2020, Pages 1-10
- (88) Michael B. Atkins, Brian I. Rini, Robert J. Motzer, Thomas Powles, David F. McDermott, Cristina Suarez, Sergio Bracarda, Walter M. Stadler, Frede Donskov, Howard Gurney, Stephane Oudard, Motohide Uemura, Elaine T. Lam, **Carsten Grüllich**, Caroleen Quach, Susheela Carroll, Beiying Ding, Qian (Cindy) Zhu, Elisabeth Piau-Louis, Christina Schiff and Bernard Escudier. Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. *Clinical cancer research*. June 2020, Volume 26, Issue 11
- (89) Cathleen Nientiedt, Volker Endris, Maximilian Jenzer, Josef Mansour, Nassim Tawanaie Pour Sedehi, Carine Pecqueux, Anna-Lena Volckmar, Jonas Leichsenring, Olaf Neumann, Martina Kirchner, Shirin Hoveid, Philippa Lantwina, Katrin Kaltenecker, Svenja Dieffenbacher, Claudia Gasch, Luisa Hofer, Desiree Franke, Georgi Tosev, Magdalena Görtz, Viktoria Schütz, Jan-Philipp Radtke, Joanne Nyarangi-Dix, Gencay Hatiboglu, Tobias Simpfendorfer, Gita Schönberg, Sanjay Isaac, Dogu Teber, Stefan A. Koerber, Georgia Christofi, Elena Czink, Rebecca Kreuter, Leonidas Apostolidis, Clemens Kratochwil, Frederik Giesel, Uwe Haberkorn, Jürgen Debus, Holger Sültmann, Stefanie Zschäbitz, Dirk Jäger, Anette Duensing, Peter Schirmacher, Carsten Grüllich, Markus Hohenfellner, Albrecht Stenzinger, Stefan Duensing. "High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-naïve metastatic prostate cancer—Results from a prospective pilot study using a 37 gene panel." In *Urologic Oncology: Seminars and Original Investigations*. Elsevier, April 2020.

**Cumulative Impact: 450, H-Index: 20**

Patents:

Vlcfa-containing lipids as prognostic and predictive marker for cancer therapies  
WO2020182995A1; 17.9.20

Inventor: Carsten GRÜLLICH, Andreas Mock, Stefanie ZSCHÄBITZ

## EXPERIENCE CLINICAL TRIALS

- 1994-96 Phase III, Neutropenic fever, SI
- 1995-96 Phase I, Solid Tumors, SI
- 1995-96 Phase I, Solid Tumors, PI
- 2000-02 Phase II, Leukemia, SI
- 2000-06 Phase II, Allogeneic transplantation, SI
- 2002-05 Phase III, GvHD, PI
- 2005-07 3 phase III trials, NSCLC, SI
- 2008-11 Phase I, Pancreatic cancer, SI
- 2008-11 Phase III, Liver cancer, SI
- 2010-11 Phase III, Liver cancer, PI
- 2010-13 RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy rainbow IMCL CP12-0922, **Principal investigator (PI)**
- 2011-12 An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies, **Principal investigator (PI)**
- 2011-13 A randomized, controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic renal cell carcinoma, **Principal investigator (PI)**
- 2011-12 Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer **Principal investigator (PI)**
- 2011-14 A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory Prostate Cancer, **Principal investigator (PI)**
- 2012-16 An open-label, Phase I, dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY 2010112 given once daily by subcutaneous administration in subjects with castration-resistant prostate cancer, **Principal investigator (PI)**
- 2013-14 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy, **Principal investigator (PI)**
- 2013-20 Molekulare Determinanten für Therapieansprechen beim metastasierten Nierenzellkarzinom.(MORE) IIT-Heidelberg **National study leader**
- 2014-15 A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who Are Asymptomatic or Minimally Symptomatic, **Principal investigator (PI)**

- 2014-15 A Phase II, Multicenter, Single-Arm Study of Nivolumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer, **Principal investigator (PI)**
- 2015-16 An open label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in high risk and intermediate risk patients with prostate cancer **Principal investigator (PI) (AMG and MPG) Eudra CT Nr. 2013-004489-32.**
- 2015-16 A Phase III, open-label, multicenter, randomized study to investigate the efficacy and safety of MPDL3280A (Anti-PD-L1 Antibody) compared with chemotherapy in patients with locally advanced or metastatic urothelial bladder cancer after failure with platinum-containing chemotherapy, **Principal investigator (PI)**
- 2015-16 A phase III, open-label, randomized study of MPDL3280A (Anti-PDL1 Antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma. **National study leader (LKP)**
- 2016-18 VXM01 phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy to examine safety, efficacy, and immune biomarkers after treatment with VXM01 **National study leader (LKP)**
- 2016-18 A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumors **National study leader (LKP)**
- 2016-18 A phase 3 randomized, double blind, placebo-controlled, multicenter study of the analgesic efficacy and safety of the subcutaneous administration of tanezumab (PF-04383119) in subjects with cancer pain predominantly due to bone metastasis receiving background opioid therapy. **National study leader (LKP)**
- 2017-19 A phase Ib study of the Pan FGFR Inhibitor BAY1163877 in metastatic urothelial cancer. **Principal investigator (PI)**
- 2017-19 A Phase II, multicenter, randomized, placebo-controlled, double-blind study of MOXR0916 in combination with Atezolizumab versus Atezolizumab alone in patients with untreated locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-based therapy. **National study leader (LKP)**
- 2017-19 A randomized phase II study with NIVolumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor (NIVOSWITCH). **PI**
- 2017-19 A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma – SUNNIFORECAST. **PI**
- 2017-19 A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate 9KD:CHECKpoint pathway and nivolumab clinical Trial Evaluation 9KD) **National study leader (LKP)**
- 2018-19 A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) vs. Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC). **National study leader (LKP)**
- 2019- A Phase 2, randomized non-comparative, open-label study of NKTR-214 in combination with nivolumab and of chemotherapy in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients with low PD-L1 expression. Eudra CT No.: 2018-003636-79 **PI**
- 2019- A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. EUDRACT Number 2016-001928-54. **PI**

2020- A Phase 2, Multicenter, Randomized, Double-Blind, Active-Control Study to Evaluate the Efficacy and Safety of Nivolumab Administered in Combination with IPI-549 Compared to Nivolumab Monotherapy in the Treatment of Patients with Immune Therapy-Naïve, Advanced Urothelial Carcinoma. EudraCT # 2019-000854-69. **National study leader (LKP)**

---

Place, date

---

Signature